Personalized Cancer Treatment: Molecular Vulnerabilities & Precision Oncology
Featuring: Padman Vamadevan, MD, Travis Christofferson, MS
In short
Precision oncology specialists Padman Vamadevan, MD, and Travis Christofferson, MS, of Astron Health explain how analyzing a tumor's unique molecular profile — through genomic, RNA, and protein testing — can reveal treatment targets that standard protocols often miss. They walk through how a specialized AI system, trained on over 100,000 peer-reviewed papers and reviewed by human experts, turns that raw data into a ranked, evidence-backed treatment plan, including repurposed drugs that may never reach FDA approval through conventional channels. The approach is aimed at advanced cancer patients who want more than a one-size-fits-all plan and are willing to work with their doctor to explore it.
- •Ask your oncologist about comprehensive molecular testing: a pan-cancer gene panel (50–150 genes), RNA sequencing, and if possible proteomics or immunohistochemistry — these go beyond standard biopsies and can reveal specific drivers of your cancer.
- •Standard genomic reports often stop at diagnosis; ask specifically for a report that translates your molecular results into ranked, actionable treatment options with supporting evidence.
- •Repurposed drugs — medications already approved for other conditions — may target your cancer's molecular vulnerabilities; bring this up with your doctor and ask whether any are supported by your molecular profile.
- •If your current doctor isn't open to precision oncology approaches, Astron Health works exclusively through clinicians but can connect you with a partner clinician; a personalized research report currently costs $1,150 in the US.
Watch on Cancer Patient Lab YouTube
Ask anything about this — free, no signup
Instant answers grounded in real guidelines, not the internet.
Target Your Molecular Vulnerabilities with Personalized Cancer Treatment" (Padman Vamadevan, MD, and Travis Christofferson, MS) Brad Power and Nanthana Ravichandran September 3, 2025 “We want to make precision oncology equitable. We want to make it scalable. And we want to make it as impactful as we can today, across the globe. We don't want to wait for future drugs or future technologies. Those will come, and those will be absolutely vital.
The patients I'm seeing are getting younger and younger. We're not talking about, or we shouldn't be talking about, 5-year survival anymore. We need to be talking about 20-year survival. ” – Padman Vamadevan, MD “When I look at the healthcare system within this realm of oncology, what you notice is a vast underutilization of the Pharmacopeia (the list of drugs and the ways they can be used).
It comes to pharmacology, where, on average, these small molecules affect a dozen relevant cellular pathways, but due to financial reasons, they will never get FDA approval… It's a systemic failure in the system the way the system is structured.
Meeting Summary
Many advanced cancer patients and their loved ones seek more than the "standard of care" - the generally accepted testing and treatment guidelines. They want personalized, evidence- based treatment plans that reflect the unique biology of their cancer, their values, and their goals.
They may be exploring beyond conventional protocols but lack the scientific expertise or time to evaluate which interventions are best evidenced to target the potential drivers of their disease or what these drivers could potentially be. There is a huge amount of scientific research available, but very little of it is applied to individual patients.
With 100,000s of cancer research papers published, it is impossible for any doctor to keep up, no matter how experienced, much less a patient or caregiver. Padman Vamadevan, MD, and Travis Christofferson, MS, are uniquely qualified to lead a conversation about personalizing treatment plans to an individual patient. Padman is Co- Founder and Chief Medical Officer at Astron Health, and Travis is Chief Scientific Officer.
Astron Health acts as a personal cancer research team, using advanced bioinformatics, bespoke machine learning, and best-in-class scientific experts to make sense of this research and apply it to each patient’s case. Padman Vamadevan read for a degree in Natural Sciences from Queens’ College, Cambridge, then obtained his medical degree from King’s College, London, and subsequently trained in Academic Clinical Pharmacology.
Over the past decade, he has focused on streamlining pathways to personalized cancer treatments by integrating cutting-edge molecular approaches at the intersection of Clinical Pharmacology, Metabolic Oncology, and Precision Theranostics.
A recognized thought leader in the strategic use of repurposed drugs as adjunctive cancer treatments, Dr Vamadevan leverages complex molecular data and the latest peer-reviewed research to develop precision therapies that target each patient’s unique cancer profile.
Travis Christofferson is a leading figure and thought leader in modern oncology and the “Target Your Molecular Vulnerabilities with Personalized Cancer Treatment" (Padman Vamadevan, MD, and Travis Christofferson, MS) author of "Curable, Ketones: The Fourth Fuel", and "Tripping Over the Truth".
He earned a bachelor's degree in molecular biology from Montana State University's Honors College and a master's in material engineering and science from the South Dakota School of Mines and Technology. As a former full-time science writer and founder of the Foundation for Metabolic Cancer Therapies, Travis brings extensive expertise to Astron's research initiatives.
Why can personalizing your cancer treatment be better than following the "standard of care"?
•Cancer is highly heterogeneous, meaning your tumor has unique molecular characteristics, specific mutations, and molecular pathways driving your cancer.
•“Standard of care” treatments are often generalized and may not target the specific vulnerabilities of your cancer.
•You can explore targeted interventions beyond traditional chemotherapy, or using existing drugs in more strategic, personalized ways, potentially improving treatment effectiveness and reducing unnecessary toxicity. What are the key tests to enable personalized treatment?
•A pan-cancer panel of 50-150 genes (genomics DNA sequencing)
•RNA sequencing (transcriptomics)
•Proteomics or at minimum immunohistochemistry (including tests like PDL1) How can your data be translated into a personalized treatment strategy?
•Use a large language model trained on peer-reviewed papers with your specific genetic mutations and medical profile to identify potential treatments (Extract meaningful drug- gene and pathway associations (using “named entity recognition”, a technique for identifying data types, organizing them, and making associations
•Prioritize interventions based on scientific evidence, mechanistic plausibility, individual patient context, and safety
•Manually curate AI-generated recommendations by scientific experts
•Provide a data-driven treatment hypothesis ranked by strength and supported by references Can you use ChatGPT or other AI engines for finding promising treatments? A customized AI-system can address the problem of personalization in cancer care. For example, Astron’s model looks in depth at:
•Information sources : Should you use peer-reviewed cancer research papers, guidelines, or a general knowledge base?
•Weighting: Your scoring approach should consider literature quality, mechanistic plausibility, disease context, and safety. “Target Your Molecular Vulnerabilities with Personalized Cancer Treatment" (Padman Vamadevan, MD, and Travis Christofferson, MS)
•Expert review: You should have human experts review and validate the AI-generated recommendations.
•Treatment scope: Do you want to consider standard cancer drugs, non-cancer drugs, off-label uses of cancer drugs, nutraceuticals, and lifestyle modifications? Other AI tools may not have the specificity and guardrails required to flag safe and well- evidenced interventions specific to your case. How can you keep current with the latest research?
•Continuously scan and process new research papers
•Consider study design quality, clinical validation, disease specificity
•Have experts who understand cancer complexity and can critically evaluate new research review and curate the data How can you access personalized cancer treatment services?
•Get comprehensive molecular testing (a pan-cancer panel of 50-150 genes, full RNA sequencing, and if possible, proteomics or immunohistochemistry)
•Work with your current doctor or find a doctor willing to refer you to help order the treatment strategy report, interpret it, and potentially implement the recommendations
•; the current cost of a research report is approximately $1,150 in the US; they will review your molecular testing reports and provide a personalized research report with potential treatment strategies. How can you learn more about personalizing your cancer treatment?
•Be proactive in discussing molecular profiling and potential targeted treatments with your medical team; consult with doctors who are open to integrative and precision medicine approaches
•Explore services that provide detailed molecular analysis and personalized treatment recommendations (for example, contact Astron Health through their website to book a free consultation)
•Stay informed about the latest research in precision oncology
•Read the meeting summaries or watch the video recordings of conversations we have had with other providers of personalized treatment services:
•• • • • • • •
•“Target Your Molecular Vulnerabilities with Personalized Cancer Treatment" (Padman Vamadevan, MD, and Travis Christofferson, MS) The information and opinions expressed on this website or platform, or during discussions and presentations (both verbal and written) are not intended as health care recommendations or medical advice by Cancer Patient Lab, its principals, presenters, participants, or representatives for any medical treatment, product, or course of action. You should always consult a doctor about your specific situation before pursuing any health care program, treatment, product or other course of action that might affect your health. “Target Your Molecular Vulnerabilities with Personalized Cancer Treatment" (Padman Vamadevan, MD, and Travis Christofferson, MS) Meeting Notes KEYWORDS Precision oncology, molecular profiling, personalized treatment, bioinformatics platform, drug repurposing, synthetic lethality, longitudinal data, empirical outcomes, clinical trials, patient- centric, integrative oncology, molecular tumor board, data-driven, public health impact, therapeutic interventions. SPEAKERS Padman Vamadevan (61%), Travis Christofferson (20%), Brad Power (12%), Richard Anders (6%), Will LaValley (1%), Raphael Leong (<1%) CHAT CONTRIBUTORS Russ Hollyer, Rick Davis, Allen Morris, Helen, Richard Anders, Alexander Lalov, Raphael Leong SUMMARY Padman Vamadevan and Travis Christofferson from Astron Health discussed their precision oncology approach. They highlighted the limitations of conventional oncological treatments and the potential of personalized molecular profiling. Astron Health's platform uses bioinformatics and large language models to analyze raw molecular data, creating personalized low-toxicity intervention plans. They emphasized the importance of empirical data and longitudinal studies. A case study on colon cancer demonstrated their methodology, using repurposed drugs like celecoxib and caffeine. The service costs £950 in the UK and $1,150 in the US, aiming to make precision oncology accessible and scalable. Access
•Clinicians are the key decision-makers, as Astron Health sells exclusively through clinicians in the US.
•Patients can request their physicians to use Astron Health's services.
•If a patient's physician is not willing to refer, Astron Health can work with the patient to refer them to one of their partner clinicians. Cost
•The cost to patients in the US is currently $1,150.
•In the UK, the cost is 950 pounds.
•As the report generation becomes more automated, the cost to patients is expected to decrease significantly.
•They hope to semi-automate the process so that it becomes a clinician-level function, with the cost attributable to the clinician and patients receiving the report as a bonus of working with that clinician. Competition “Target Your Molecular Vulnerabilities with Personalized Cancer Treatment" (Padman Vamadevan, MD, and Travis Christofferson, MS)
•ChatGPT was mentioned as a potential alternative for analyzing genetic mutations and suggesting treatments.
•Astron Health differentiates itself by having a bespoke LLM trained on over 100,000 peer-reviewed papers and a weighted evidence system.
•They claim their approach is more comprehensive and safer than using ChatGPT, which could potentially suggest harmful treatments. Objections
•Some conventional oncologists may be reluctant to prescribe repurposed drugs because it's outside their wheelhouse.
•The complexity of the data and the need for frequent testing might be overwhelming for some clinicians.
•Regulatory considerations were mentioned as a reason for selling exclusively through clinicians in the US. Need
•Conventional oncological treatment options sometimes fall short.
•There's a huge technological overhang that clinical medicine struggles to keep up with.
•Most molecular testing reports end at a diagnostic stage, not providing clear, actionable treatment strategies.
•Precision oncology has historically been viewed as expensive, inaccessible, and often inefficient. Questions
•How does Astron Health manage the complexity of all the omics data and treatment recommendations?
•How does Astron Health's approach compare to using ChatGPT or other AI engines for finding promising studies?
•What types of molecular testing does Astron Health recommend (e.g., WGS, WES, proteomics, RNA)?
•How does Astron Health keep its data current with new research? OUTLINE Introductions, Overview of Astron Health and Personalized Treatment
•Padman Vamadevan from London and Travis Christofferson from Lake Placid, New York, co-founders of Astron Health, discussed precision oncology and services provided by Astron Health.
•The new paradigm uses molecular profiling to develop personalized treatment strategies.
•There are limitations of conventional oncological treatments and a need for personalized approaches. Challenges in Precision Oncology “Target Your Molecular Vulnerabilities with Personalized Cancer Treatment" (Padman Vamadevan, MD, and Travis Christofferson, MS)
•The challenges in precision oncology include the vast amount of research data and the need for personalized treatment protocols.
•A bioinformatics platform is needed to translate raw molecular data into personalized treatment strategies.
•Precision oncology should be accessible and efficient for all cancer patients, with a focus on interventions that are already available and being prescribed safely. Case Study and Methodology
•Travis Christofferson presented a sample case report from a patient with colon cancer.
•He explained the methodology used to identify valuable targets and drug repurposing strategies, for example, the use of myricetin to inhibit MEK1 and MEK2, and caffeine as a direct inhibitor of PIK3CA. Clinical Trials and Data Integration
•The current process uses manual curation with a goal of automating the bioinformatics pipeline.
•Longitudinal data collection is important.
•There are challenges in managing complex data. Challenges, Conclusions, and Future Directions
•There are cost, accessibility, and effectiveness issues in getting personalized services.
•The goal is to make precision oncology equitable and scalable.
•Existing drugs are underutilized.
•There is a need for a more comprehensive approach to cancer treatment. “Target Your Molecular Vulnerabilities with Personalized Cancer Treatment" (Padman Vamadevan, MD, and Travis Christofferson, MS)
Full transcript
Brad Power This is the Cancer Patient Lab. We’re honored to have with us Padman Vamadevan, who's in London, and Travis Christofferson, who is in Lake Placid, New York, although he's normally in Colorado. They're going to be leading a discussion with us about their approach to precision oncology and some of their services. This webinar is for information purposes only and not medical advice.
We try to arm our patients and caregivers with information they can take to their medical team. We are nonprofit 501(c)(3), and we depend on the kindness of people who make donations to bring you services like this webinar. You can do that very easily on our website, where there's a prominent donate button. Padman Vamadevan 1:13 Thank you so much for inviting us here today, Brad and to all of you for showing up. My name's Dr. Padman Vamadevan.
I'm the co-founder and Chief Medical Officer here at Astron Health, based in London. Although we have a very cross Atlantic team, I'm here together with my co- founder, Travis Christofferson, and also one of our founder associates, Raphael Leong.
Today, we just wanted to introduce you to a new paradigm that we believe could fundamentally enhance the way that clinicians can use molecular profiling to develop robust, personalized treatment strategies for patients like yourselves.
“Target Your Molecular Vulnerabilities with Personalized Cancer Treatment" (Padman Vamadevan, MD, and Travis Christofferson, MS) Having watched a few of the Cancer Patient Lab videos, I think they are a phenomenal source of education for patients and clinicians and scientists alike. We know that patients like you understand the complexity and heterogeneity of cancer.
As you know, conventional oncological treatment options can sometimes fall short, and the reason we built Astron was to try and give each patient and each doctor the confidence that they are doing absolutely everything possible to personalize cancer treatment based on molecular science.
Before Astron, we spent over a decade together at a biotech that worked trying to develop real world clinical studies looking at the potential of drug repurposing as adjunctive treatments in cancer. So very much in addition to standard of care, sometimes we saw the power of these approaches, but we also saw their limits when they were used generically.
Some patients did better than expected, but unfortunately, too many plateaued, too many relapsed, and so often we felt that we were treating the disease using over generalized principles, rather than targeting the specific vulnerabilities of that individual patient's cancer.
And an example of this was a study that we published in 2019 in glioblastoma multiforme, where the top line was that in 96 patients, the median survival of those patients was almost double expected. But unfortunately, when we looked a little bit deeper at the patient cohort that was driven by about 40% of extreme responders, we really were unsatisfied with that.
We wanted to do more for the other 60% and we thought that the thing that we were missing was the personalization of our approach. We were using the same standardized adjunctive protocol for every single patient, and some were benefiting and others weren't.
And trying to translate that overhang where we were trying to sort of match all the research data that was out there into personalized treatment protocols was something that we just couldn't keep up with. There are thousands of studies being published every year, hundreds of molecular vulnerabilities in each tumor type.
We're barely scratching the surface and that's why we built a strong bioinformatics platform powered by large language “Target Your Molecular Vulnerabilities with Personalized Cancer Treatment" (Padman Vamadevan, MD, and Travis Christofferson, MS) models that becomes your personal cancer research team. It's designed to be built for patients and their clinicians.
Want to learn more about your specific case?
Upload your medical records and ask Navis questions tailored to your diagnosis.